跳至主要内容
临床试验/CTRI/2017/08/009226
CTRI/2017/08/009226尚未招募未知

A randomized, double blind, placebo control study to assess the efficacy and safety of OLNP-05 capsule versus placebo for the treatment of subjects with premature ejacuation

Olene Life Sciences Private Limited0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Male subjects, aged >= 21 years to <= 60 years at the time of informed consent
  • 2. Subject having a monogamous, heterosexual relationship and expected/planned to maintain this relationship for the duration of study
  • 3. Subjects having baseline Intravaginal Ejaculatory Latency Time (IELT) of <2 minutes
  • 4. Subjects meeting with diagnostic criteria for premature ejaculation (PEP score >=11)
  • 5. Subject and his partner agreeing to attempt sexual intercourse 2 times/ week and to use stopwatch during the intercourse
  • 6. Subject willing to give written informed consent and willing to comply with trial protocol

排除标准

  • 1. Previous events or other conditions that may affect premature ejaculation/erectile dysfunction, including but not limited to spinal trauma or pelvic surgery
  • 2. Subjects with genital anatomical deformities including but not limited to penile deformities
  • 3. Subjects for whom sexual activity is inadvisable because of their underlying disease status.
  • 4. Sexual dysfunction in female partner, painful intercourse, partners with decreased interest in intercourse or other forms of sexual dysfunction.
  • 5. Subjects with significant and uncontrolled hematological /metabolic/ endocrinologial/ respiratory/ cardiovascular/ neurological/psychiatric/liver/ gastrointestinal/kidney diseases or other significant pathological conditions which as judged by Invesutigator may affect subject participation in the study
  • 6. Any concomitant treatment which is not permissible
  • 7. Continuing history of alcohol and / or drug abuse
  • 8. Recent participation in another clinical trial or receive some other drug during the study besides that in the protocol that known to alter the pharmacokinetics/pharmacodynamic profile of the study drug.
  • 9. Subject having a known allergy to any of the ingredients of investigational prodcut
  • 10. Any other condition that in the opinion of the Investigator does not justify the subjectâ??s participation in the study.

研究者

相似试验